BMO Capital analyst Evan David Seigerman maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $40 to $70.
EXCLUSIVE: Streamlining The Cannabis Industry – Collaboration, Data Sharing In The Supply Chain
The cannabis industry is growing rapidly as the demand for marijuana and its by-products rise, leading to heightened competition and the need for efficient and profitable streamlined operations.